About | Free Trial

Last Update


This profile was last updated on . .

Is this you? Claim your profile.

Wrong Andrew Mazar?

Dr. Andrew Mazar P. PhD

Consulting Head of Product Development

Lung Therapeutics Inc

HQ Phone: (512) 872-7527

Lung Therapeutics Inc

7500 Rialto Blvd. Ste 250

Austin, Texas 78735

United States

Company Description

Lung Therapeutics, Inc. is a pharmaceutical company focusing on lung diseases especially targeting orphan drug indications and other currently untreatable or neglected lung diseases. This is our commitment. Based in Austin, Texas, Lung Therapeutics Inc.... more

Find other employees at this company (5)

Background Information

Employment History

Chief Scientific Officer

Attenuon , LLC

Development Consultant

Wilson Therapeutics


Member of Study Sections
National Institutes of Health

Managing Member and Consulting Chief Scientific Officer
Tactic Pharma LLC

Tactic Pharmaceuticals


University of Illinois College of Medicine

Web References (77 Total References)

Team | Lung Therapeutics, Inc.

www.lungtx.com [cached]

Andrew Mazar, Ph.D.

Founder and Head of Product Development

Andrew P. Mazar, Ph.D., Lung ...

www.lungtx.com [cached]

Andrew P. Mazar, Ph.D., Lung Therapeutics' Co-Founder and Consulting Head of Product Development, said, "Having consulted on other EU orphan drug submissions in the past, I know how challenging the process can be.

Press Room | Lung Therapeutics, Inc.

www.lungtx.com [cached]

Andrew Mazar, Ph.D. Biography

Founder and Head of Product Development
Recent News
Andrew Mazar, Ph.D.

Home > Andrew Mazar, ...

www.lungtx.com [cached]

Home > Andrew Mazar, Ph.D.

Andrew Mazar, Ph.D.
Andrew Mazar, Ph.D.
Founder and Head of Product Development
Dr. Mazar serves as Head of Product Development in addition to his current position as Director of the Center for Developmental Therapeutics and Entrepreneur-in-Residence at Northwestern University. Prior to this, Dr. Mazar was most recently the Chief Scientific Officer at Attenuon, LLC and has led three projects at Attenuon through IND and into phase II trials. He is currently managing an additional three projects at various stages of IND enabling development. Prior to Attenuon, Dr. Mazar had significant input in three projects that led two successful INDs, two of which made it through phase II trials and one of which is currently in phase II trials. One of these projects was the original development of scuPA for the treatment of myocardial infarction. Thus, Dr. Mazar has extensive expertise in translating early stage science into clinical projects through phase II clinical development and managing this entire process. He also has direct experience in the development of LTI-01 (scuPA) as a clinical therapeutic agent.
During his tenure in biotechnology, Dr. Mazar has led several projects that culminated in several out-license deals as well as funded collaborations. A new partnership deal with a large European venture group on all of Attenuon's projects has closed. During the partnership process, Dr. Mazar led early and late stage discussion with most every large and mid-size biotechnology company interested in cancer therapeutics. During these discussions, terms sheets were obtained from five different suitors, all of them public companies. While at Attenuon, Dr. Mazar managed $63M of investment capital, the majority of this raised through a single investor, during his nine year tenure and led a road show managed by Bank of America.

About Us | Panther Biotechnology, Inc.

pantherbiotechnology.com [cached]

Andrew P. Mazar Ph.D. (Consulting VP of R&D): Dr. Mazar is a twenty year veteran of oncology drug discovery and development. He is internationally recognized for his basic research work on the role of the urokinase plasminogen activator (uPA) system in tumor progression and angiogenesis. He led R&D at two start-up companies in San Diego and has been responsible for advancing numerous drug candidates from discovery through mid-stage clinical trials. Dr. Mazar is an Associate Editor for Recent Patent Reviews on Anti - Cancer Drug Discovery and a member of the editorial board of Clinical Cancer Research. He has served on study sections for the NIDDK, NHLBI, NIH Special Emphasis Panels, VA Oncology Merit Review, AHA and the Phillip Morris External Research Program. Dr. Mazar is a reviewer for numerous journals and is the co-author of 98 peer reviewed publications.

Similar Profiles

Other People with this Name

Other people with the name Mazar

Miroslav Mazar
Molson Coors Brewing Company

Leah Mazar

Denise Mazar
Colonial Intermediate Unit 20

Ryan Mazar
Grey Healthcare Group

Holly Mazar

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory